Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
B36.0
Niacin – Forschung
Hilft vermutlich
277 begutachtete Studien
Was die Evidenz sagt
Hilft vermutlich
Niacin half in etwa der Hälfte (6/11) der Studien, die einen Effekt gemessen haben — vielversprechend, aber nicht einhellig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1983–2026 mit einer typischen Studiengröße von 918 Teilnehmenden.
Basierend auf 277 Studien · 33 Meta-Analysen · 217 RCTs · 374,867 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
6geholfen4unklar1nicht geholfen· 266 weitere ohne bewertete Effektdaten
Nach Outcome
Cholesterol & lipidsErhöht HDL und verändert das Lipidprofil bei pharmakologischen Dosierungen · 4-8 Wochen
Hilft vermutlich246 Studien
Niacin flush & tolerability
Gemischte Evidenz94 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung26 Studien
Heart & blood pressureErhöht HDL und verändert das Lipidprofil bei pharmakologischen Dosierungen · 4-8 Wochen
Überwiegend Mechanismus / Beobachtung16 Studien
Skin health
Hilft wahrscheinlich14 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung13 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung12 Studien
Longevity & agingErhöhte NAD+-Spiegel für die zelluläre Gesundheit · Fortlaufend
Überwiegend Mechanismus / Beobachtung7 Studien
Energy & fatigue
Zu wenige bewertete Studien2 Studien
Pellagra & niacin deficiency
Zu wenige bewertete Studien1 Studie
Neuroprotection & brain aging
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 37 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
88%
über Studien hinweg
Untersuchte Personen
375k
typische Studie: 918 Personen
Stärkste Designs
250
33 gepoolt, 217 randomisiert
Zeigte Nutzen
55%
6/11 Studien
Wie lange Studien liefen
Unter einer Woche
1
1–3 Monate
2
3+ Monate
1
Untersuchte Populationen
Healthy adults3
General population2
Patients on lipid-lowering therapies1
Type 2 diabetes patients in primary care1
Stetige Forschung
45 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
198320042026
1Lipoprotein(a) levels reductionMeta-Analysen=145,314 · very large study2025
Einfach gesagt: Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels.
Xie S et al. · Atherosclerosis (2025)
Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels.
Further research is necessary to understand whether this effect would translate into a clinically relevant cardiovascular benefit.
2Triglyceride reductions and HDL cholesterol levelsMeta-Analysen=14,223 · very large study2023
Einfach gesagt: Low to very low certainty evidence established chromium supplements as the most effective in reducing fasting blood glucose levels and homeostasis model assessment of insulin resistance (SUCRAs: 90...
Xia J et al. · Pharmacological research (2023)
Low to very low certainty evidence established chromium supplements as the most effective in reducing fasting blood glucose levels and homeostasis model assessment of insulin resistance (SUCRAs: 90.4% and 78.3%, respectively).
Vitamin K supplements ranked best in reducing glycated hemoglobin A1c and fasting insulin levels (SUCRAs: 97.0% and 82.3%, respectively), with moderate to very low certainty evidence.
Vanadium supplements ranked best in lowering total cholesterol levels with very low evidence certainty (SUCRAs:100%).
3Carotid intima-media thickness reductionMeta-Analysen=8,762 · very large study2021
Einfach gesagt: Statins combined with niacin performed a greater CIMT reduction compared to high-intensity statins alone and combination therapies with ezetimibe.
Li H et al. · European journal of clinical pharmacology (2021)
Statins combined with niacin performed a greater CIMT reduction compared to high-intensity statins alone and combination therapies with ezetimibe.
The advantage of niacin-combined statins therapies to improve cardiovascular endpoint needs further validation through randomized controlled trials.
5Treatment discontinuation due to side effectsMeta-Analysen=39,195 · very large study2017
Einfach gesagt: Moderate- to high-quality evidence suggests that niacin does not reduce mortality, cardiovascular mortality, non-cardiovascular mortality, the number of fatal or non-fatal myocardial infarctions, nor the number of fatal or non-fatal strokes but is associated with side effects.
Schandelmaier S et al. · The Cochrane database of systematic reviews (2017)
Sehr groß Schaden
← SchlechterKein EffektBesser →
Participants randomised to niacin were more likely to discontinue treatment due to side effects than participants randomised to control group (RR 2.17, 95% CI 1.70 to 2.77; participants = 33,539; studies = 17; I2 = 77%; moderate-quality evidence).
Moderate- to high-quality evidence suggests that niacin does not reduce mortality, cardiovascular mortality, non-cardiovascular mortality, the number of fatal or non-fatal myocardial infarctions, nor the number of fatal or non-fatal strokes but is associated with side effects.
Benefits from niacin therapy in the prevention of cardiovascular disease events are unlikely.
6Lipoprotein(a) levelsMeta-Analysen=9,013 · very large study2016
Einfach gesagt: In this meta-analysis of randomized placebo-controlled clinical trials, treatment with nicotinic acid was associated with a significant reduction in Lp(a) levels.
Sahebkar A et al. · Metabolism: clinical and experimental (2016)
Groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Meta-analysis suggested a significant reduction of Lp(a) levels following ER niacin treatment (weighted mean difference - WMD: -22.90%, 95% CI: -27.32, -18.48, p<0.001).
Results also remained similar when the meta-analysis was repeated with standardized mean difference as summary statistic (WMD: -0.66, 95% CI: -0.82, -0.50, p<0.001).
When the studies were categorized according to the administered dose, there was a comparable effect between the subsets of studies with administered doses of <2000mg/day (WMD: -21.85%, 95% CI: -30.61, -13.10, p<0.001) and ≥2000mg/day (WMD: -23.21%, 95% CI: -28.41, -18.01, p<0.001).
Einfach gesagt: The areas of neurology and psychiatry have shown great advances regarding the deepening of knowledge in prophylaxis and pathophysiology, as well as in the treatment of established diseases.
Nogueira-de-Almeida CA et al. · Central nervous system agents in medicinal chemistry (2023)
According to the GRADE instrument, most studies (>50%) followed a controlled clinical study model and had a good methodological design.
The areas of neurology and psychiatry have shown great advances regarding the deepening of knowledge in prophylaxis and pathophysiology, as well as in the treatment of established diseases.
The recognition of the role of nutrition as an adjunct to these processes is currently growing.